The study of the reactivity of three 1-(2-dimethylaminoethyl)-1H-pyrazole derivatives of general formula [1-(CH 2 ) 2 NMe 2 }-3,5-R 2 -pzol] {where pzol represents pyrazole and R_H (1a), Me (1b) (5c)}. Compounds 4c and 5c arise from the orthometallation of the 3-phenyl ring of ligand 1c. Complex 2a has been further characterized by X-ray crystallography. Ligands and complexes were evaluated for their in vitro antimalarial against Plasmodium falciparum and cytotoxic activities against lung (A549) and breast (MDA MB231 and MCF7) cancer cellular lines. Complexes 2a-2c and 5c exhibited only moderate antimalarial activities against two P. falciparum strains (3D7 and W2). Interestingly, cytotoxicity assays revealed that the platinacycle 4c exhibits a higher toxicity than cisplatin in the three human cell lines and that the complex 2a presents a remarkable cytotoxicity and selectivity in lung (IC 50 = 3 μM) versus breast cancer cell lines (IC 50 N 20 μM). Thus, complexes 2c and 4c appear to be promising leads, creating a novel family of anticancer agents. Electrophoretic DNA migration studies in presence of the synthesized compounds have been performed, in order to get further insights into their mechanism of action.
In the search of new metallodrugs avoiding toxicity and resistance, special attention has been paid to the replacement of one or both NH 3 ligands of cisplatin by other N-donor ligand(s). This strategy gave rise to oxaliplatin and picoplatin [8] (Fig. 1) . In oxaliplatin, which is active in patients with colorectal cancer, both NH 3 units have been replaced by (1R,2R)-cyclohexane-1,2-diamine (R,R-dach); while picoplatin, that is in clinical development for the treatment of patients with solid tumors, contains a 2-methylpyridine instead of one NH 3 ligand.
The search of novel N-donor ligands (i.e. amines, oximes, imines or azoles) for the synthesis of optimized platinum(II) and palladium(II) drugs is still in progress [9, 10] . In addition, it is well-known that azoles are valuable reagents in coordination chemistry and that their binding to a transition metal ion affects their properties and activities. Few complexes with pyrazole ligands showing an antitumor activity similar to that of cisplatin have been reported [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , but the effect produced by the substituents on the heterocycle has not been clarified so far. Within this therapeutic context, and in order to clarify this point and to elucidate the influence of mode of binding of this family of ligands in the biological activity of the complexes, we decided to synthesize the new pyrazole derivatives 1a-1c ( Fig. 1 ) and to study their reactivity with Pt(II) and Pd(II). Due to the relative disposition of the two nitrogen atoms, compounds 1a-1c may bind to the M(II) center as a neutral (N) or (N,N′) ligand. Moreover, for 1c, the presence of the phenyl ring on position 3 of the heterocycle may also allow the formation of metallacycles containing 1c as a mer-terdentate (C,N,N′) − ligand.
Cyclometallated complexes derived from N-donor ligands have attracted great interest during the last decade due to their properties and applications in a wide variety of fields [10, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and compounds of this kind containing Pd(II), Pt(II), Ru(II), Ir(III) Rh(III) and Au have shown promising cytotoxic activities [10, 20, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Few cyclopalladated complexes derived from pyrazole are known [37] [38] [39] [40] [41] and, to the best of our knowledge, their cytotoxicity has only been reported once [41] . On the other hand despite the interest for Pt(II) complexes, platinacycles with pyrazolyl ligands are scarce and studies on their biological activity have not been performed so far.
In this work, we present the study of the reactivity of ligands 1a-1c with syntheses of cis-[MCl 2 (DMSO) 2 ], the new compounds 2a-2c and 3a-3c and the cyclometallated complexes 4c and 5c, together with a comparative study of their antineoplastic activity against lung (A549) and breast (MDA MB231 and MCF7) human cancer cell lines. As our interests lie also in the area of antiparasitic drugs [42, 43] and since a few Pt(II) [44] and Pd(II) based complexes [45] with antimalarial activity (in the micromolar range) have been reported, we also tested the potential of the free ligands (1a-1c) and the complexes 2a-5c against the chloroquine-susceptible strain (3D7) and the chloroquine-resistant strain (W2) of Plasmodium falciparum.
Experimental

Chemistry
Materials and methods
Reagents were obtained from commercial sources and used as received. Cis-[MCl 2 (DMSO) 2 ] (M_Pd or Pt) were prepared according to literature protocols [46, 47] . All reactions were carried out with dry and freshly distilled solvents. Column chromatography refers to flash chromatography and was carried out on SiO 2 (13) ; N(1)\C(1),1.339 (6) ; N(1)\N(2), 1.370 (6) ; N(3)\C(7), 1.499 (5) ; N(3)\C(6), 1.499 (7) ; N(3)\C(8), 1.506(6); C(1)\C(2), 1.409(8); C (2)\C(3), 1.367(10); C(3)\N(2), 1.349 (7) ; N(2)\C(5), 1.453(7); C(5)\C(6), 1.483 (7) ; N (1)\Pt\N(3), 93.57 (15) ; N(1)\Pt\Cl(1), 176.60 (11) , N(3)\Pt\Cl(1), 89.61 (12) ; N (1)\Pt\Cl(2), 89.32 (12) ). (from 2% to 5%)} to yield 28 mg ( 
Crystallography
A prismatic crystal of 2a (sizes in Table 1 ) was selected and mounted on a MAR345 diffractometer with an image plate detector. Unit-cell parameters were determined from 5843 reflections (3°b θb 31°) and refined by least-squares method. Intensities were collected with graphite monochromatized Mo K α radiation. 9754 reflections were measured (in the range 2.39°≤ θ≤32.38°) of which 2861 were non-equivalent by symmetry {R int (on I)= 0.072} and 2741 reflections were assumed as observed applying the condition I N 2σ(I). Lorentz-polarization and absorption corrections were made.
The structure was solved by Direct methods using SHELXS computer program [48] and refined by full-matrix least-squares method with SHELX97 computer program [49] . All H atoms were computed and refined, using a riding model, with an isotropic temperature factor equal to 1.2 times the equivalent temperature factor of the atom to which is linked. The final R(on F) factor was 0.033, wR(on |F| 2 ) = 0.085 and goodness of fit = 1.062 for all observed reflections. Number of refined parameters was 118. Max. shift/esd= 0.00, Mean shift/esd = 0.00. Max. and min. peaks in final difference synthesis were 2.767 and −2.054 eÅ −3 , respectively. 2 Compounds 3a and 3b retain solvents. Evidence of the presence of small amounts of toluene is in the 1 H NMR spectra (a singlet at 2.3 ppm). Despite the fact that the two compounds were dried in the vacuum for a week, it was impossible to evaporate the solvents. The best analytical results are presented above. 
Cell proliferation assay
The assay was performed by a variation of the method described by Mosmann et al. [51] as specified by Matito and coworkers [52] . In brief, 3×10 3 A549 cells/well were cultured in 96 well plates. Concentrations that inhibited cell growth by 50% (IC 50 ) after 72 h of treatment were calculated based on the survival rate compared with untreated cells. Relative cell viability was measured by the absorbance on an ELISA (enzymelinked immunosorbent assay) plate reader (Tecan Sunrise MR20-301, TECAN, Salzburg, Austria) at 550 nm.
Cell viability assay
The compounds were dissolved in 100% DMSO at 50 mM as stock solution. Then, serial dilutions have been done in DMSO (1:1), in this way DMSO concentrations in cell media were always the same. Finally, 1:500 dilutions of the serial dilutions of compounds on cell media were done. The assay was performed as described by Givens et al. [53] . In brief, MDA MB231 and MCF7 cells were plated at 5000 and 10,000 cells/well, respectively, in 100 μL media in tissue culture 96 well plates (Cultek). After 24 h, media was replaced by 100 μL/well of serial dilution of drugs. Control wells did not contain compounds. Each point concentration was run in triplicate. Reagent blanks, containing media plus colorimetric reagent without cells were run on each plate. Blank values were subtracted from test values and were routinely 5-10% of uninhibited control values. Plates were incubated 72 h. Hexosaminidase activity was measured according to the following protocol: the media containing was removed and cells were washed once with PBS 60 μL of substrate solution (p-nitrophenol-N-acetyl-β-D-glucosamide 7.5 mM [Sigma N-9376], sodium citrate 0.1 M, pH 5.0, 0.25% Triton X-100) was added to each well and incubated at 37°C for 1-2 h; after this incubation time, a bright yellow appears; then, plates could be developed by adding 90 μL of developer solution (glycine 50 mM, pH 10.4; EDTA 5 mM), and absorbance was recorded at 410 nM.
DNA migration studies
Plasmid pBluescript SK+ was obtained using a QIAGEN plasmid midi kit as described by the manufacturer. Interaction of drugs with pBluescript SK+ plasmid DNA (Stratagene) was analyzed by agarose gel electrophoresis following a modification of the method described by Abdullah et al. [54] . In brief, plasmid DNA aliquots (40 μg/mL) were incubated with different concentrations of the platinum and palladium compounds (ranging from 5 μM to 100 μM) at 37°C for 24 h. For comparison, cisplatin was used as a positive control. Aliquots of 20 μL of compound: DNA complexes containing 0.8 μg of DNA were subjected to 1% agarose gel electrophoresis in TAE buffer (40 mM Tris-acetate, 2 mM EDTA, pH 8.0). The gel was stained in the same buffer containing ethidium bromide (0.5 mg.mL ) and visualized and photographed under UV light.
In vitro antimalarial assay
The 3D7 chloroquine-susceptible P. falciparum clone (Africa) and the W2 chloroquine resistant clone (Indochina) were maintained in culture in RPMI 1640 (Invitrogen, Paisley, United Kingdom), supplemented with 10% human serum (Abcys S.A., Paris, France) and buffered with 25 mM HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 25 mM NaHCO 3 . Parasites were grown in A-positive human blood under controlled atmospheric conditions that consisted of 10% O 2 , 5% CO 2 and 85% N 2 at 37°C with a humidity of 95%. All strains were synchronized twice with sorbitol before use. Clonality was verified using PCR genotyping of polymorphic genetic markers, msp1, msp2 and microsatellite loci [55, 56] .
Chloroquine (CQ) diphosphate was purchased from Sigma (Saint Louis, MO). CQ was suspended in water in concentrations ranging from 5 to 3200 nM. Compounds 1-5 were suspended in methanol and then diluted in RPMI to obtain final concentrations ranging from 0.01 μM to 500 μM.
For in vitro isotopic microtests, 25 μL/well of antimalarial drug and 200 μL/well of the parasitized red blood cell suspension (final parasitemia, 0.5%; final hematocrit, 1.5%) were distributed into 96 well plates. Parasite growth was assessed by adding 1 μCi of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were then incubated for 48 h in controlled atmospheric conditions. Immediately after incubation, the plates were frozen and thawed to lyse erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; Perkin-Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin-Elmer). Filter microplates were dried, and 25 μL of scintillation cocktail (Microscint O; Perkin-Elmer) was placed in each well. Radioactivity incorporated by the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).
The IC 50 , the drug concentration able to inhibit 50% of parasite growth, was assessed by identifying the drug concentration corresponding to 50% of the uptake of tritiated hypoxanthine by the parasite in the drug-free control wells. The IC 50 value was determined by nonlinear regression analysis of log-based dose-response curves (Riasmart TM , Packard, Meriden, USA). IC 50 are expressed as means of 3 to 4 experiments ± standard deviation.
Results and discussion
Synthesis and characterization
The preparation of ligands 1a and 1b was carried out by a modification of former literature protocols [57, 58] consisting in the alkylation of 1H-pyrazole and 3,5-dimethyl-1H-pyrazole respectively with 2-dimethylaminoethyl chloride using sodamide as a base (Scheme 1). The best yield for the synthesis of 1c was obtained by alkylation of 3,5-diphenyl-1H-pyrazole using Aliquat 336 as a phase transfer catalyst. The three ligands were fully characterized by NMR, IR and mass spectroscopy. To the best of our knowledge, these data were found to be absent or incomplete in the literature.
The The new complexes were characterized by elemental analyses, mass spectrometry, infrared spectroscopy and 1 H, 13 C and two-dimensional homo (gCOSY) and heteronuclear (gHSQC and gHMBC) correlations. In the 13 C{ 1 H} NMR spectra of cyclometallated compounds 4c and 5c the intensity of the signal due to the C 2′ atom decreased substantially and was low-field shifted when compared with that of the free ligand 1c. In addition, no evidence of cross-peak between the resonance of the C 2′ nuclei and those of the aromatic protons was detected in the [ 1 H-
13
C]-HSQC spectra of compounds 4c and 5c. According to previous studies [59, 60] , these observations suggested the existence of a σ(M-C 2′ ) bond and the presence of five membered ring metallacycle in 4c and 5c.
195
Pt{ 1 H} NMR spectra not only provided convincing evidence of the coordination sphere of the platinum and structure of 2c and 4c, but also explained the variations produced by the different mode of binding of ligand 1c. The spectrum of 2c showed a singlet at −2165 ppm, the position of which is consistent with the values reported for related complexes with a "(N,N′)Cl 2 " environment around the platinum(II) [60] [61] [62] . For 2c the signal appeared at higher fields (δ=−3555 ppm); this trend agrees with those reported for complexes containing R\CH =N\(CH 2 ) n NMe 2 (R = phenyl or ferrocenyl moieties) as bidentate (N,N′) or terdentate (C,N,N′)
− ligands [61, 62] . The
Pt NMR spectrum of 2b was not recorded due to the low solubility of this product and for 2a, two singlets of relative intensities (1.0:0.3) centered at δ=−2178 and −2982 ppm were observed. The chemical shift of the former one is similar to that of 2c and the presence of the second and less intense signal suggested that this product is less stable in CDCl 3 than its analog 2c.
Complex 2a was also characterized by X-ray diffraction. Its molecular structure and the atom numbering scheme are presented in Fig. 2 In the crystal a molecule at (x, y, z) is connected to two different and vicinal ones [at (x, 1 + y, z) and (−1 + x, y, z)] by four weak intermolecular C\H···Cl interactions (Fig. 3) forming chains.
Biological studies
A human lung carcinoma cell line (A549) and two human breast cancer cell lines (MDA MB231 and MCF7) were used to test the cytotoxic activity of the synthesized compounds. Cisplatin was used as a positive control, showing a value of IC 50 below 20 μM in the three cancer cellular lines (Table 2) .
For the purely organic ligands 1a-1c, a moderate activity was observed for the 3,5 diphenyl substituted compound 1c (IC 50 values between 52 and 64 μM). In all cases, the Pd(II) and Pt(II) complexes were more potent than their corresponding parent ligand and compound 2a exhibited in human lung A549 cancer cell line the highest potency (IC 50 =3 μM) of the synthesized complexes and a notable selectivity for lung cancer cell line versus the two breast cancer cell lines (MDA MB 231 and MCF7) selected. Interestingly, 2a turned out to be three times more potent than cisplatin in lung A549 cancer cell line. In the three cancer cell lines, the platinacycle 4c exhibited the highest cytotoxic activity with IC 50 values in the range of 6.2-9.3 μM. It was more effective against human lung carcinoma (A549) cells and breast cancer (MDA MB231 and MCF7) cells than the reference drug cisplatin. Cytotoxicity effectiveness of 4c was approximately twice that of the coordination complex 2c in the three cancer cell lines. Compound 4c arises from the coordination of the two nitrogen atoms and the formation of a σ(Pt\C) bond, this leads to a [6.5.5.6] tetracyclic system. Consequently, it has a higher degree of rigidity and planarity than 2c. It is well-known that square-planar metal complexes with aromatic ligands bind to DNA by intercalation [71] [72] [73] [74] and consequently compound 4c may behave not only as alkylating but also as an intercalating agent. This potential dual behavior may account for the increased potency of the platinacycle 4c when compared with 2c.
Although compounds 4c and 5c only differ by the nature of the M(II) ion, the platinum(II) complex 4c is (2.6-5.5 times depending on the cell line) more potent than its Pd(II) analog 5c. This may be due to the greater lability and faster hydrolysis rate of palladium complexes compared to their platinum equivalents [75] . Therefore, higher cytotoxicity of 5c could be also connected to slower hydrolysis of Pt\Cl bond and to the stability of this compound compared to the palladium(II) derivative 5c.
The effect of binding of the compounds investigated in this study on supercoiled DNA was determined by their ability to alter the electrophoretic mobility of pBluescript plasmid DNA: supercoiled closed circular (cc) and open circular (oc) forms. Fig. 4 shows the electrophoretic mobility of native pBluescript DNA incubated with the synthesized compounds (1c and 2-5) at 5 μM or 50 μM concentration. To provide a basis for comparison, incubation of DNA with cisplatin was also performed using the same concentrations and conditions. As expected, at both 5 μM and 50 μM concentrations, cisplatin greatly altered the electrophoretic mobility of pBluescript DNA. At 5 μM concentration, none of the assayed compounds produced a significant effect on the electrophoretic mobility of native pBluescript DNA. At this concentration, the mobility of the supercoiled closed circular form was only slightly decreased by the platinum(II) compound 2a and the palladium(II) compound 5c. Consistently, at 50 μM, both compounds greatly alter the mobility of plasmid DNA. For these two compounds (2a and 5c), an unwinding assay was performed with increasing amounts of drugs ranging from 5 μM to 100 μM (Fig. 5) . For complex 2a, the migration rate of supercoiled band decreases until it comigrates with the nicked relaxed band. In this titration experiment of 40 μg/mL pBluescript, the coalescence point, defined as the amount of platinum complex that is necessary for complete removal of all supercoils from DNA, occurs with 50 μM concentration of 2a. The lowest efficiency of complex 2a than cisplatin in removing the supercoils from DNA could be related to the shorter incubation time (24 h) of the experiments compared to the incubation time in the experiments with cancer cell lines (72 h). Under these conditions, hydrolysis of the platinum complex should not occur. For the palladium(II) compound 5c, the rate of migration of supercoiled band also decreases as drug concentration increases up to 10 μM. At higher concentrations the migration rate begins to increase again in parallel to a decrease in the bands intensity. At higher concentrations of 5c (more than 100 μM), DNA is no longer visible.
Regarding the other assayed complexes (Fig. 4) , at 50 μM concentration, small changes on the migration rate of the supercoiled closed circular plasmid DNA were observed for most of them, with the exception of the free ligand 1c and the platinum(II) complex 4c. When assayed at higher concentrations (500 μM), the synthesized compounds dramatically altered plasmid DNA mobility (data not shown). Again, compounds 1c and 4c did not produce any effect. Paradoxically, as it was mentioned before, complex 4c exhibited a great cytotoxicity in the three selected human cancer cell lines.
Overall, these results indicated that most of the compounds investigated in this study interact with DNA, 2a and 5c exhibiting the highest effect on plasmid DNA mobility. These two compounds may behave as alkylating agents acting by the same mechanism as cisplatin. However, compound 4c is hypothesized to act on tumor cells through a different mechanism than cisplatin.
We also evaluated the potential activities of products 1-5 against the chloroquine-susceptible strain (3D7) and the chloroquine-resistant strain (W2) of P. falciparum (Table 3 ). The free ligands exhibited poor (for 1a-1b) to moderate (for 1c) antimalarial activities. In contrast with these results, the platinum(II) complexes (2a-2c) with a (N,N′)Cl 2 environment demonstrated higher in vitro activity against P. falciparum chloroquine-susceptible and chloroquine-resistant clones than their corresponding parent ligand. The toxicity of platinacycle 4c was low on P. falciparum parasites (IC 50 of 111.7 μM on 3D7 and 138.0 μM on W2). The cyclopalladated complex 5c was 10-times more potent than its platinum(II) analog 4c against P. falciparum. Compound 2c showed similar cytotoxic activity on P. falciparum parasites and cancer cells. Compound 5c was 2 to 3-times more potent against P. falciparum parasites than against cancer cells.
In vivo efficiency of platinum derivatives has been already demonstrated in malaria. Cisplatin (Fig. 1 ) cured mice infected with Plasmodium berghei at a dose of 6 mg/kg body weight [76] . The Pd-cyclometallated derivative 5c was more efficient than Pt-protoporphyrin against P. falciparum (38 μM) [77] . However, these compounds were less potent against the two P. falciparum clones 3D7 and W2 than Fe-derivatives, such as ferroquine and analogs [78, 79] , ferrocenic derivatives from ciprofloxacin [80] , or Ru, such as ruthenoquine and analogs [42] .
Conclusions
The study of the reactivity of the three pyrazolyl ligands was evaluated against one chloroquine susceptible strain 3D7 and three chloroquine-resistant strains W2 of P. falciparum. Compounds 2a-2c and 5c were found to exhibit significant in vitro activity (with IC 50 in the microM range). On the contrary, compound 4c was inactive in similar experimental conditions. The evaluation of the in vitro cytotoxic activity of complexes 2c-5c revealed that they exhibit growth inhibitory activity against lung (A549) and breast (MDA MB 231 and MCF7) human cancer cell lines. The comparison of the results obtained for the three types of complexes in human carcinoma A549 cell line indicates that the obtained IC 50 values follow the trend 2ab 4cb cisplatinb 2b b 2cb 5cb 3bb 3a. This means that: a) the platinum(II) derivatives are more potent than their palladium(II) analogs, b) for the platinum(II) complexes the change of binding mode of the ligand from (N,N′) in 2c to (C,N,N′) in 4c increases the cytotoxic activity, and c) compound 2a is specially relevant due to remarkable potency in lung cancer A549 cell line (twice that of 4c and three times more potent than cisplatin). It is noteworthy that complex 4c, the first example of a pyrazole containing platinacycle, shows greater antitumoral in vitro activity than cisplatin. The platinum and palladium complexes evaluated in this study more or less exhibit an effect on DNA electrophoretic mobility. Complexes 2a and 5c are those exhibiting the strongest interaction with DNA, and both display moderate to good cytotoxic activities towards different cancer cell lines. In particular complex 2a is the most potent of the new synthesized compounds in human lung carcinoma A549 cell line (IC 50 value of 3 μM). An exception occurs in the case of compound 4c that exhibits a considerable cytotoxicity in several cancer cell lines but has no effect on plasmid DNA mobility. These results underscore the importance of additional factors in predicting anticancer activity. New Pt-and Pd-cyclometallated derivatives will be synthetized to improve antimalarial activity. Finally it should be noted that the methods and strategies described here, especially those concerning complex 4c, constitute the first step toward the development of new but closely related platinum(II) complexes with pincer (C,N;N′) 
